Phospho pp2ay307

α-minimal essential medium, fetal bovine serum and antibiotic/antimycotic solution were from Life Technologies. All other reagent-grade chemicals, including BSA and fatty acids, were obtained from Sigma–Aldrich unless otherwise stated. Wortmannin and okadaic acid were from Calbiochem-Merck. Fraction V fatty acid-free BSA was from Roche. Insulin was from R&D systems. Complete protein phosphatase inhibitor tablets were purchased from Roche Diagnostics. Phospho-Akt^Thr308, phospho-Akt^Ser473, phospho-ERK1/2^{Thr202/Tyr204}, phospho-GSK3^Ser21/9, phospho-CREB^Ser133, phospho-Src^Tyr416, anti-Akt and anti-ERK1/2 antibodies were from Cell Signaling Technology. Anti-GSK3 and anti-PTEN antibodies were from Santa Cruz Biotechnology. Anti-IR (insulin receptor), anti-p85, anti-IRS1 and anti-PP2A subunit C, demethylated were from Millipore. Anti-β actin and anti-GAPDH were from Sigma. Phospho-PP2A^Y307 was from Abcam.

Antibodies for IL-1β, caspase-1, PP2A, and phospho-PP2A (Y307) were obtained from Abcam. NLRP3 and ASC antibodies were provided by R&D Systems and Adipogen respectively. Other antibodies used in this study include: β-actin (Proteintech Group), IBA-1 (GeneTex), TRPV1 (Alomone labs), Goat Anti-Rabbit IgG-HRP (CST), Goat Anti-Mouse IgG-HRP (CST), Goat Anti-Rat IgG-HRP (Proteintech Group), Dylight 488, Goat Anti-Rabbit IgG (Abbkine), Dylight 488, Goat Anti-Mouse IgG (Abbkine), Dylight 594, Goat Anti-Rabbit IgG (Abbkine), Dylight 594, and Goat Anti-Mouse IgG (Abbkine).
PAMPs used in this study were LPS (Escherichia coli 0111: B4, L2630, Sigma), ATP (MedChemExpress), and Nigericin sodium salt (MedChemExpress). Chemical inhibitors and reagents include: Capsazepine (CPZ, MedChemExpress), BAPTA-AM (MedChemExpress), Okadaic acid (OA, Beyotime Biotechnology), Z-VAD-FMK (MedChemExpress), Fluo-3 AM (Dojindo), and Pluronic F-127 (Sigma).